Biogen and Eisai’s next disease-modifying Alzheimer’s drug candidate, lecanemab, has been granted FDA priority review, signaling that a decision could be made by early…
Cholinesterase inhibitor drugs could help turn back the clock on Alzheimer’s symptoms by treating cognitive impairment. More than a third people over the age…
Biogen’s Alzheimer’s drug aducanumab encounters another bump in the road as the FDA delays its approval decision. The Federal Drug Administration has given itself…
In yet another encouraging step toward the development of what could be the first drug approved for Alzheimer’s disease, the Federal Drug Administration today…
Whether it’s diet, exercise or air pollution, researchers are constantly investigating lifestyle and environmental factors that may play a role in the progression or…
The U.S. Food and Drug Administration (FDA) has approved a re-dosing study for patients formerly enrolled in Biogen’s phase three clinical trials of its…
An experimental “seaweed” drug called Oligomannate, which treats Alzheimer’s, is now available for patients to buy in China. Chinese officials announced conditional approval to…